The Effect of Aging on Quality of Life in Acromegaly Patients Under Treatment

Yamamoto, Naoki; Urai, Shin; Fukuoka, Hidenori; Yamamoto, Masaaki; Suzuki, M.; Shichi, Hiroki; Fujita, Yasunori; Kanie, Keitaro; Iguchi, Genzo; Takahashi, Yutaka; Ogawa, Wataru

doi:10.3389/fendo.2022.819330

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1), of which seven reported absolute values. In these seven studies, scores of refractory acromegaly patients compared to patients in remission varied substantially, described as either comparable in the two patient groups in four studies [44][45][46][47], decreased in one study [38], or decreased except for the domain personal relations in another study [48] (Table 1). One study compared refractory acromegaly patients to healthy controls, finding lower scores in all domains for refractory patients [49].…”

Section: Disease-specific Hr-qolmentioning

confidence: 99%

“…AcroQoL Acromegaly Quality of Life Questionnaire, IQR interquartile range, SMS( +) on somatostatin analogue treatment, SMS(−) not on somatostatin analogue treatment, ↓ significantly lower compared to acromegaly patients in remission; ↑ significantly higher compared to acromegaly patients in remission, no P-value reported, = tested and no significant difference compared to patients in remission a Patients received octreotide LAR every two weeks (dose not reported) b Psychological subscales c AcroQoL scores did not differ between refractory patients and patients in remission at 24 weeks d No significant difference between all refractory patients SMS (+) or SMS (−) and patients in remission. No subgroup analysis performed for SMS(+) and SMS(−) separately e Refractory patients scored significantly lower than healthy controls f Values estimated based on figure, absolute values were not presented g Patients received weekly intramuscular injections of octreotide LAR 20 mg. At 12 weeks a dose escalation to octreotide LAR 30 mg was permitted in case GH > 2.5 ug/L and/or IGF1 above upper limit of normal for age, but this was not obligatory Chin [47] Gu [44] Guo [38] Hua [46] Psaras [49] Trepp [48] Yamamoto [45] Guo [38] SF-12 Psaras [49] Alcalar [54] Nader [50] d Psaras [49] Vega-Beyhart [52] Ye [53]…”

Section: Disease-specific Hr-qolmentioning

confidence: 99%

“…49 [42][43][44][45][46][47][48][49][50][51][52] Role physical 23 [19][20][21][22][23][24][25][26][27][28][29][30] Bodily pain 65 [60][61][62][63][64][65][66][67][68][69][70] General health 28 [22][23][24][25][26][27][28][29][30][31][32][33][34] Social functioning 53 [50][51][52][53][54]…”

Section: Physical Functioningmentioning

confidence: 99%

See 2 more Smart Citations

Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need

2023

View full text Add to dashboard Cite

Purpose To describe quality and outcomes of patient-reported outcome (PRO) measures (PROMs) used in patients with refractory hormone-producing pituitary adenomas, and to provide an overview of PROs in these challenging pituitary adenomas. Methods Three databases were searched for studies reporting on refractory pituitary adenomas. For the purpose of this review, refractory adenomas were defined as tumors resistant to primary therapy. General risk of bias was assessed using a component approach and the quality of PROM reporting was assessed using the International Society for Quality of Life Research (ISOQOL) criteria. Results 20 studies reported on PROMs in refractory pituitary adenomas, using 14 different PROMs, of which 4 were disease specific (median general risk of bias score: 33.5% (range 6–50%) and ISOQOL score: 46% (range 29–62%)). SF-36/RAND-36 and AcroQoL were most frequently used. Health-related quality of life in refractory patients (measured by AcroQoL, SF-36/Rand-36, Tuebingen CD-25, and EQ-5D-5L) varied greatly across studies, and was not always impaired compared to patients in remission. Conclusion There is a scarcity of data on PROs in the subset of pituitary adenomas that is more difficult to treat, e.g., refractory and these patients are difficult to isolate from the total cohort. The patients' perspective on quality of life, therefore, remains largely unknown in refractory patients. Thus, PROs in refractory pituitary adenomas require adequate analysis using properly reported disease specific PROMs in large cohorts to enable appropriate interpretation for use in clinical practice.

show abstract

Section: Disease-specific Hr-qolmentioning

confidence: 99%

Section: Disease-specific Hr-qolmentioning

confidence: 99%

See 1 more Smart Citation

Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need

2023

View full text Add to dashboard Cite

show abstract

Improved health by combining dietary restriction and promoting muscle growth in DNA repair‐deficient progeroid mice

Vermeij,

Alyodawi,

van Galen

et al. 2024

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundAgeing is a complex multifactorial process, impacting all organs and tissues, with DNA damage accumulation serving as a common underlying cause. To decelerate ageing, various strategies have been applied to model organisms and evaluated for health and lifespan benefits. Dietary restriction (DR, also known as caloric restriction) is a well‐established long‐term intervention recognized for its universal anti‐ageing effects. DR temporarily suppresses growth, and when applied to progeroid DNA repair‐deficient mice doubles lifespan with systemic health benefits. Counterintuitively, attenuation of myostatin/activin signalling by soluble activin receptor (sActRIIB), boosts the growth of muscle and, in these animals, prevents muscle wasting, improves kidney functioning, and compresses morbidity.MethodsHere, we investigated a combined approach, applying an anabolic regime (sActRIIB) at the same time as DR to Ercc1Δ/− progeroid mice. Following both single treatments and combined, we monitored global effects on body weight, lifespan and behaviour, and local effects on muscle and tissue weight, muscle morphology and function, and ultrastructural and transcriptomic changes in muscle and kidney.ResultsLifespan was mostly influenced by DR (extended from approximately 20 to 40 weeks; P < 0.001), with sActRIIB clearly increasing muscle mass (35–65%) and tetanic force (P < 0.001). The combined regime yielded a stable uniform body weight, but increased compared with DR alone, synergistically improved motor coordination and further delayed the onset and development of balance problems. sActRIIB significantly increased muscle fibre size (P < 0.05) in mice subjected to DR and lowered all signs of muscle damage. Ercc1Δ/− mice showed abnormal neuromuscular junctions. Single interventions by sActRIIB treatment or DR only partially rescued this phenotype, while in the double intervention group, the regularly shaped junctional foldings were maintained. In kidney of Ercc1Δ/− mice, we observed a mild but significant foot process effacement, which was restored by either intervention. Transcriptome analysis also pointed towards reduced levels of DNA damage in muscle and kidney by DR, but not sActRIIB, while these levels retained lower in the double intervention.ConclusionsIn muscle, we found synergistic effects of combining sActRIIB with DR, but not in kidney, with an overall better health in the double intervention group. Crucially, the benefits of each single intervention are not lost when administered in combination, but rather strengthened, even when sActRIIB was applied late in life, opening opportunities for translation to human.

show abstract

Quality of life in patients with acromegaly: a scoping review

Wang,

Yang,

Huang

2024

Orphanet J Rare Dis

View full text Add to dashboard Cite

Purpose To evaluate the available evidence regarding the quality of life (QoL) in patients with acromegaly, by synthesizing the psychosocial factors of QoL, QoL measures, and complementary interventions targeting QoL. Methods A scoping review was conducted using the PRISMA-ScR guideline. We searched six English databases (PubMed, Embase, CINAHL, Scopus, Web of Science, and the Cochrane Library) from the inception to August 21, 2023. We included observational studies involving psychosocial factors and complementary interventions targeting QoL (concept) in patients with acromegaly (population) in any setting (context). The design characteristics, psychosocial factors, measures, details of interventions, and outcomes of included studies were described in detail. Results Twenty-one studies were identified, including sixteen cross-sectional studies and five interventional studies. Ten categories of psychosocial factors that are associated with QoL in acromegaly. Depression and anxiety were the most frequent psychosocial factors. Seven different validated QoL measures were used. AcroQoL was the most common measure. Two categories of complementary interventions targeting QoL were identified including psychological and exercise interventions. Conclusions Our scoping review provides a reasonably clear picture of the current research status of QoL in acromegaly. However, this review also highlights the need to deepen understanding of QoL and psychosocial factors in the future, as well as conduct longitudinal research and qualitative research to clarify the changing trends of psychosocial factors and specific experiences of patients. Further, more potential clinical complementary interventions are needed to improve QoL for patients with acromegaly.

show abstract

The Effect of Aging on Quality of Life in Acromegaly Patients Under Treatment

Cited by 4 publications

References 39 publications

Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need

Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need

Improved health by combining dietary restriction and promoting muscle growth in DNA repair‐deficient progeroid mice

Quality of life in patients with acromegaly: a scoping review

Contact Info

Product

Resources

About